Cabozantinib, targeting VEGFR1-3, receptor tyrosine kinase (KIT), tropomyosin receptor kinase B (TRKB), anexelekto receptor tyrosine kinase (AXL), Rearranged during transfection (RET), tyrosine kinase MET, Fms-like tyrosine kinase-3 (FLT-3), TEK receptor tyrosine kinase (TIE2), for hepatocellular and renal cell carcinomas, and Medullary thyroid cancer. Here, TEK is linked to medullary thyroid gland carcinoma.